Company intelligence / Profile preview

Midnight Pharma

Ownership: Private
Development stage: Other

Overview

Midnight Pharma was an early-stage biopharmaceutical company focused on developing Almorexant, a novel small molecule orexin receptor antagonist for the treatment of insomnia and related sleep disorders. The lead program reached Phase 2 clinical development but was ultimately discontinued. No active programs or recent clinical results are reported as of May 2025.

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

Actelion Pharmaceuticals Ltd. (originator of Almorexant; partnership/licensing relationship implied by drug origin)

Beyond the preview

Go deeper on Midnight Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Midnight Pharma.

Explore the full profile